FlandersBio on Twitter

Follow us on Twitter

Archive for March 2013 - News

Archive for March 2013 - Nieuws

in het nederlands in english

FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.

Mediconsult becomes “Trends Gazelle” Company third year in a row

28.03.2013

Mediconsult, the outsourcing division of Vandycke & Partners, the well-known recruitment agency in Healthcare, has made the list of Trends Gazelle companies 2013 for the third year running and has achieved one of its highest rankings thus far. The list is published annually and contains an overview of fastest growing companies in Belgium that enhance the competitive ability of a region and influence the entrepreneurial climate in a positive way. Making the list three consecutive years is very rare for any company. Mediconsult is thrilled with the award. read more

Genetic risk factors breast prostate and ovarian cancer exposed

27.03.2013

An international consortium – including scientists from VIB, KU Leuven and UZ Leuven – has identified more than 80 regions in our DNA that increase a person’s risk of developing breast, prostate and ovarian cancer. It is the first time that this type of study has been performed on such a large scale. Diether Lambrechts (VIB/KU Leuven) coordinated the Belgian part of the study into risk factors for breast cancer and ovarian cancer. read more

Galapagos to start Phase 2a study with GLPG0974 in IBD patients

27.03.2013

Galapagos NV (Euronext: GLPG) announced today that GLPG0974, an inhibitor of FFA2 (free fatty acid receptor 2, formerly known as GPR43) being developed to treat chronic neutrophil-driven inflammatory conditions such as inflammatory bowel disease (IBD), showed a clean safety profile and a strong biomarker signal. In this second Phase 1 study with GLPG0974, the safety, tolerability, pharmacodynamics and pharmacokinetics were evaluated in 32 healthy volunteers dosed for 2 weeks. The positive outcome of this study supports progression to a Proof of Concept study in ulcerative colitis patients that is expected to start in 2Q 2013. read more

Galapagos gives R&D Update

27.03.2013

Galapagos NV (Euronext: GLPG) will give an R&D Update today in New York City, highlighting the progress and plans for its portfolio of more than 40 research and development programs. read more

Join E-news

Interested in a regular update of the life sciences and biotech sector in Flanders? Subscribe to our newsletter.

Subscribe now

Back to top

Print